This week, the White House announced a deal with Eli Lilly and Novo Nordisk to lower the cost of their GLP-1 weight loss ...

The REMODEL trial testing semaglutide’s efficacy in patients with CKD and T2DM also employed MRI, transcriptomics, blood and urine samples, and kidney biopsies to clarify the drug’s effects.

Study also revealed no increased risk for major adverse cardiovascular events for patients on a GLP-1 RA versus those not on a GLP-1 RA.

As Pfizer acquires MET-097 maker Metsera, phase 2 data show potential for greater tolerability and once-monthly dosing.

New obesity drugs that were designed to treat diabetes and obesity are increasingly being used off-label by people without ...

GLP-1 RA use was associated with significant weight loss in patients with IBD and obesity and/or T2D, with mean differences of -9.1 kg in semaglutide users, -9 kg in liraglutide users, and -11.6 kg in ...

CG-0416, a highly liver-targeted THR-<BETA> agonist, demonstrates high-quality weight loss by reducing fat mass while preserving muscle, both as a monotherapy and in combination with GLP-1 RAs.

Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics ...

People with Type 2 diabetes who combined healthy lifestyle habits with GLP-1 receptor agonist (GLP-1 RA) medications had a greater reduction in risk of major adverse cardiovascular events, including ...

Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, today announced ...

Novo Nordisk NVO is a dominant player in the cardiometabolic space, which markets its blockbuster semaglutide-based (GLP-1) ...